Clinical Solutions for Biotech
Assyro AI empowers clinical development professionals in biotechnology companies with intelligent regulatory tools. Assyro AI supports clinical development professionals with regulatory intelligence for trial design, IND submissions, and global clinical requirements. Navigate the regulatory landscape confidently from Phase 1 to NDA.
What Clinical Teams Do
- Designing and executing clinical trials
- Preparing IND and CTA submissions
- Ensuring GCP compliance across trial sites
- Managing clinical data and trial documentation
- Interacting with health authorities on clinical matters
Challenges in Biotech
- Understanding country-specific clinical trial requirements
- Navigating evolving clinical trial regulations post-COVID
- Managing decentralized trial regulatory considerations
- A 5-person RA team is handling work that used to require a department of 15
- First IND prep takes 8-12 weeks because everything is manual and fragmented
How Assyro AI Helps
- Track clinical trial regulations across global markets
- Monitor FDA clinical holds and trial suspensions
- Generate IND and CTA documentation
- Compress IND prep from 8-12 weeks to under 3 weeks with AI-assisted drafting and validation
- Coordinate CRO deliverables in one workspace with version control and traceable handoffs
Key Skills We Support
- Clinical trial design
- GCP compliance
- IND/CTA preparation
- Protocol development
- Health authority interactions
Regulations We Cover
- 21 CFR Part 600
- ICH Q5-Q12
- FDA CBER guidance
- EMA ATMPs
- Biosimilar guidance
Frequently Asked Questions
Assyro AI provides clinical teams with regulatory intelligence on trial requirements, GCP compliance, and IND/CTA submissions. Our AI tracks clinical holds, monitors competitive developments, and helps prepare regulatory documents.
Regulatory Context
Clinical teams in Biotech depend on current regulatory intelligence to keep submissions, quality narratives, and inspection responses aligned with health-authority expectations.
Common Mistakes
- Using one-region trial assumptions for multi-jurisdiction submissions.
- Delayed protocol amendment impact assessment on filing timelines.
- Insufficient traceability from clinical decisions to regulatory rationale.
Key Regulatory Terms
- Investigational New Drug
IND is the FDA application a sponsor submits before shipping or administering an unapproved drug to human subjects, authorizing a clinical investigation rather than granting marketing approval. Studies of a lawfully marketed drug may be exempt.
- GCP
Good Clinical Practice (GCP) is the international standard governing the design, conduct, recording, and reporting of clinical trials in human participants, binding sponsors and investigators to protect participant rights and safety while making trial data verifiable.
Relevant Regulatory Intelligence
Related Actions
Other Roles in Biotech
Clinical in Other Industries
Ready to Transform Your Clinical Operations?
See how Assyro AI can accelerate regulatory work for clinical development professionals in biotechnology companies.
Schedule a Demo